Mussarat N. Rahim, Michael A. Heneghan – 13 March 2020

Thoetchai (Bee) Peeraphatdit, Jennifer Wang, Matthew A. Odenwald, Shaomin Hu, John Hart, Michael R. Charlton – 13 March 2020 – Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies. The advent of ICIs has been a major breakthrough in the field of oncology, a fact recognized by the 2018 Nobel Prize in Physiology or Medicine being awarded for the discovery.

Austin D. Schenk, W. Kenneth Washburn – 13 March 2020

Manisha Verma, Elliot B. Tapper, Amit G. Singal, Victor Navarro – 13 March 2020 – Palliative care (PC) that has evolved from a focus on end‐of‐life care to an expanded form of holistic care at an early stage for patients with serious illnesses and their families is commonly referred to as nonhospice PC (or early PC). Patients with end‐stage liver disease (ESLD) suffer from a high symptom burden and a deteriorated quality of life (QOL), with uncertain prognosis and limited treatment options.

Ghideon Ezaz, Hirsh D. Trivedi, Margery A. Connelly, Claudia Filozof, Kellie Howard, Mark L.Parrish, Misung Kim, Mark A. Herman, Imad Nasser, Nezam H. Afdhal, Z. Gordon Jiang, Michelle Lai – 13 March 2020 – Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease driven by genetic and environmental factors. MicroRNAs (miRNAs) serve as pleiotropic post‐transcriptional regulators of cellular pathways.

Injoon Yeo, Gi‐Ae Kim, Hyunsoo Kim, Ji Hyeon Lee, Areum Sohn, Geum‐Youn Gwak, Jeong‐Hoon Lee, Young‐Suk Lim, Youngsoo Kim – 13 March 2020 – There is an urgent need for new biomarkers that address the shortcomings of current screening methods which fail to detect a large proportion of cases with hepatocellular carcinoma (HCC) at early stage. To develop a robust, multiple‐biomarker panel based on multiple reaction monitoring–mass spectrometry with high performance in detecting early‐stage HCC within at‐risk populations.

Manisha Verma, Elliot B. Tapper, Amit G. Singal, Victor Navarro – 13 March 2020 – Palliative care (PC) that has evolved from a focus on end‐of‐life care to an expanded form of holistic care at an early stage for patients with serious illnesses and their families is commonly referred to as nonhospice PC (or early PC). Patients with end‐stage liver disease (ESLD) suffer from a high symptom burden and a deteriorated quality of life (QOL), with uncertain prognosis and limited treatment options.

Tatsuya Taniguchi, Alana Zanetti‐Yabur, Pijun Wang, Mykhaylo Usyk, Robert D. Burk, Allan W. Wolkoff – 11 March 2020 – The liver plays an essential role in removing endogenous and exogenous compounds from the circulation. This function is mediated by specific transporters, including members of the family of organic anion transport proteins (OATPs) and the Na+‐taurocholate transporting polypeptide (NTCP). In the present study, transporter protein expression was determined in liver samples from patients with cirrhosis or controls without liver disease.

Antonio Pea, Nigel B. Jamieson, Chiara Braconi – 11 March 2020 – Most of the human genome consists of DNA genes that are translated into RNAs but not into proteins. These RNA molecules are named noncoding RNAs (ncRNA). While in the past it was thought that ncRNAs would be redundant without relevant functions, it is now well established that ncRNAs identify a class of regulatory molecules that finely tune cell homeostasis and are deregulated in disease states, including hepatocellular carcinoma (HCC).

Leke Wiering, Robert Öllinger, Jochen Kruppa, Uwe Schoeneberg, Tomasz Dziodzio, Maximillian Jara, Matthias Biebl, Richard Dargie, Nathanael Raschzok, Wenzel Schöning, Dennis Eurich, Moritz Schmelzle, Igor M. Sauer, Johann Pratschke, Paul V. Ritschl – 11 March 2020 – In contrast to donor factors predicting outcomes of liver transplantation (LT), few suitable recipient parameters have been identified. To this end, we performed an in‐depth analysis of hospitalization status and duration prior to LT as a potential risk factor for posttransplant outcome.